Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study |
Zeng, Yin-Duo
(Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Zhang, Li (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) Liao, Hai (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) Liang, Ying (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) Xu, Fei (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) Liu, Jun-Ling (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) Dinglin, Xiao-Xiao (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) Chen, Li-Kun (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) |
1 | Bianco C, Tortora G, Bianco R, et al (2002). Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res, 8, 3250-8. |
2 | Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78. DOI ScienceOn |
3 | Ceresoli GL, Cappuzzo F, Gregorc V, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol, 15, 1042-7. DOI ScienceOn |
4 | Das AK, Sato M, Story MD, et al (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res, 66, 9601-8. DOI |
5 | Das AK, Chen BP, Story MD, et al (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res, 67, 5267-74. DOI |
6 | Fidler IJ, Yano S, Zhang RD, et al (2002). The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol, 3, 53-7. DOI |
7 | Furuse K, Kamimori T, Kawahara M, et al (1997). A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in nonsmall- cell lung cancer with brain metastasis. Br J Cancer, 75, 614-8. DOI |
8 | Gow CH, Chien CR, Chang YL, et al (2008). Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res, 14, 162-8. DOI |
9 | Heimberger AB, Learn CA, Archer GE, et al (2002). Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFRtyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res, 8, 3496-502. |
10 | Hotta K, Kiura K, Ueoka H, et al (2004). Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer, 46, 255-61. DOI |
11 | Huang SM, Li J, Armstrong EA, et al (2002). Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res, 62, 4300-6. |
12 | Jackman DM, Holmes AJ, Lindeman N, et al (2006). Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol, 24, 4517-20. DOI ScienceOn |
13 | Kim JE, Lee DH, Choi Y, et al (2009). Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer, 65, 351-4. DOI |
14 | Ma S, Xu Y, Deng Q, et al (2009). Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer, 65, 198-203. DOI ScienceOn |
15 | Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. DOI |
16 | Moscetti L, Nelli F, Felici A, et al (2007). Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer, 109, 274-81. DOI |
17 | Park SY, Kim YM, Pyo H (2010). Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer, 9, 222. DOI |
18 | Namba Y, Kijima T, Yokota S, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer, 6, 123-8. DOI |
19 | Nussbaum ES, Djalilian HR, Cho KH, et al (1996). Brain metastases. Histology, multiplicity, surgery, and survival. Cancer, 78, 1781-8. DOI |
20 | Olak J (1999). Surgical strategies for metastatic lung cancer. Surg Oncol Clin N Am, 8, 245-57. |
21 | Quantin X, Khial F, Reme-Saumon M, et al (1999). Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer, 26, 35-9. DOI |
22 | Shimato S, Mitsudomi T, Kosaka T, et al (2006). EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol, 8, 137-44. DOI |
23 | Shukuya T, Takahashi T, Naito T, et al (2011). Continuous EGFRTKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer, 74, 457-61. DOI ScienceOn |
24 | Takahashi H, Ohrui T, Ebihara S, et al (2004). Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer, 43, 371-2. DOI |
25 | van VM, Kal HB, Taphoorn MJ, et al (2002). Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep, 9, 683-8. |
26 | Yawn BP, Wollan PC, Schroeder C, et al (2003). Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med, 86, 32-7. |